HER Imaging and Molecular Interaction Mapping in Breast Cancer
FP7 imagint

  Partner: Innoprot
Project Leader
Isbaal Ramos PhD

Group members
Patricia Villacé
Danel Kortazar
Clarisa Salado
Jorge Gamiz

University of the Basque Country
University of Freiburg-IMTEK
Trinity college Dublin

Selected publications
Salado C, Olaso E, Gallot N, Valcarcel M, Egilegor E, Mendoza L, Vidal-Vanaclocha F. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl Med. 2011 May 12;9:59. Pubmed.

Ramos I, Martín-Benito J, Finn R, Bretaña L, Aloria K, Arizmendi JM, Ausió J, Muga A, Valpuesta JM, Prado A. Nucleoplasmin binds histone H2A-H2B dimers through its distal face. J Biol Chem. 2010 Oct 29;285(44):33771-8. Pubmed.

Valcárcel M, Arteta B, Jaureguibeitia A, Lopategi A, Martínez I, Mendoza L, Muruzabal FJ, Salado C, Vidal-Vanaclocha F. Three-dimensional growth as multicellular spheroid activates the proangiogenic phenotype of colorectal carcinoma cells via LFA-1-dependent VEGF: implications on hepatic micrometastasis. J Transl Med. 2008 Oct 9;6:57. Pubmed.

Kortazar D, Fanarraga ML, Carranza G, Bellido J, Villegas JC, Avila J, Zabala JC. Role of cofactors B (TBCB) and E (TBCE) in tubulin heterodimer dissociation. Exp Cell Res. 2007 Feb 1;313(3):425-36.Pubmed.

Villacé P, Marión RM, Ortín J. The composition of Staufen-containing RNA granules from human cells indicates their role in the regulated transport and translation of messenger RNAs. Nucleic Acids Res. 2004 Apr 30;32(8):2411-20. Pubmed.

Innoprot, who we are

Innoprot is a biotechnology company spin-off from the University of the Basque Country, with extensive R&D component located in Spain. Innoprot is provider of in vitro systems for drug discovery and development.
The company offers custom screening services for biotech and pharmaceutical partners and offers customised assay development, high throughput screening (HTS), high content analysis (HCA) and hit-to-lead optimisation services. Our staff combines experience in the field of drug discovery technologies with a broad expertise as pharmaceutical services providers.
In addition, our company is a global supplier for human and animal cells from normal cell systems with over 90 different cell types and recombinant cell lines for toxicology and screening. Many of our cell types are unique to Innoprot and therefore not currently available from any other provider in the world.
To fulfil our current activities we are used to perform tasks similar to the ones outlined in this proposal, like analyse protein-protein and RNA-protein interactions and DNA recombinant technologies. Innoprot is or has participated in several international projects (FP7-PASCA, EuroTransBio ARGIFUN and EuroNanoMed NANOSTEM).

Innoprot, task in Imagint

The task of Innoprot in the project is to identify new biomarkers implicated in breast cancer. This will be done through the isolation and characterization of the protein-protein and RNA-protein interactions in Ago2 containing complexes. Ideally this will be used in the identification of specific miRNA implicated in the antiHER2 therapies.

The Innoprot Team

Funding Bodies

more info here

more info here

more info here

more info here


   Copyright © 2011-15 - Imagint